The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD
Abstract
Introduction: Guanfacine is a noradrenergic agonist that is believed to improve symptoms of attention-deficit/hyperactivity disorder (ADHD) through selective actions at α 2A-adrenoceptors in the prefrontal cortex. A recent double-blind, multicenter trial supports the efficacy and safety of guanfacine extended release (GXR) for pediatric ADHD. This long-term, open-label extension was conducted to study the safety profile and effectiveness of GXR for up to 2 years. Methods: Subjects were 240 children 6–17 years of age with a diagnosis of ADHD who participated in the preceding randomized trial. GXR was initiated at 2 mg/day and titrated as needed in 1-mg increments to a maximum of 4 mg/day to achieve optimal clinical response. Results: The most common adverse events were somnolence (30.4%), headache (26.3%), fatigue (14.2%), and sedation (13.3%). Somnolence, sedation, and fatigue were usually transient. Cardiovascular-related adverse events were uncommon, although small reductions in mean blood pressure and pulse rate were evident at monthly visits. ADHD Rating Scale, Version IV, total and subscale scores improved significantly from baseline to endpoint for all dose groups (P<.001 for all comparisons, intent-to-treat population). Conclusion: Long-term treatment with GXR was generally safe for up to 24 months of treatment, and effectiveness was maintained over this treatment period.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These include the selective noradrenaline re uptake inhibitor atomoxetine 164 and long-acting formulations of two α2-adrenergic agonist drugs - clonidine 165 and guanfacine 166 .”
From Attention-deficit/hyperactivity disorder (2015) · cites this paper as [166]
In the citing paper
“A variety of other behavioral, developmental, and physical conditions can be comorbid in children and adolescents who are evaluated for ADHD, including emotional or behavioral conditions or a history of these problems.”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [56]
In the citing paper
“Other choices comprise medications like long acting bupropion, modafinil and guanfacine, that have all been investigated in ADHD [262,298-300].”
From European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD (2010) · cites this paper as [298]
In the citing paper
“Recently, once-daily extended-release guanfacine has proven effective in both short-term [90,91] and long-term studies [92,93].”
From Advances in understanding and treating ADHD (2011) · cites this paper as [93]
Citations
Cites
(1998) · Cited by 2,026
Barkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.111.2.279 · Cited by 1,199
Committee on Quality Improvement, S. O. A.-D. D. (2000) · Pediatrics · doi:10.1542/peds.105.5.1158 · Cited by 1,076
Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement (2001) · Pediatrics · doi:10.1542/peds.108.4.1033 · Cited by 878
Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588
Arnsten, A. F. T. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830050084013 · Cited by 458
Arnsten, A., Cai, J., & Goldman-Rakic, P. (1988) · The Journal of Neuroscience · doi:10.1523/jneurosci.08-11-04287.1988 · Cited by 391
Gillberg, C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830210105014 · Cited by 340
Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Konow, J., Lyne, A., Scherer, N., & for the SPD503 Study Group (2008) · Pediatrics · doi:10.1542/peds.2006-3695 · Cited by 317
Self-citationAn Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder
Hunt, R. D., Arnsten, A. F. T., & Asbell, M. D. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199501000-00013 · Cited by 308 · cited 1×
“tion early in the course of treatment has also been reported in other studies of guanfacine for ADHD treatment.(11)"(1322) Small decreases from baseline in mean blood pressure and pulse rate were noted at study visits, but few subjects experienced clinically significant cardiovascular-related events.”
Result
Research works printed but not linked: 1
- Sallee, J Am Acad Child Adolesc Psychiatry
Cited by
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Attention-deficit/hyperactivity disorder
Faraone, S. V., Asherson, P., Banaschewski, T., Biederman, J., Buitelaar, J. K., Ramos-Quiroga, J. A., Rohde, L. A., Sonuga-Barke, E. J. S., Tannock, R., & Franke, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.20 · Cited by 1,479
Self-citationKooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928
“Other choices comprise medications like long acting bupropion, modafinil and guan-facine, that have all been investigated in ADHD [262,298-300].”
Advances in understanding and treating ADHD
Antshel, K. M., Hargrave, T. M., Simonescu, M., Kaul, P., Hendricks, K., & Faraone, S. V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-72 · Cited by 140
Metadata
- Authors
- Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A.
- Affiliations
- Massachusetts General Hospital (US)
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2008-12
- Volume
- 13
- Issue
- 12
- Pages
- 1047-1055
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- OpenAlex
- W181776045
- Cited by
- 270
- References
- 24
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 162 · 2019: 6 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 7 · 2014: 14 · 2013: 10 · 2012: 14
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Spectrums (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- guanfacine extended release, attention deficit hyperactivity disorder, children with ADHD, long-term treatment safety, efficacy, alpha2A-adrenoceptor, sleepiness, sedation, blood pressure reduction, ADHD Rating Scale-IV
- MeSH terms
- Adolescent, Adrenergic alpha-Agonists, Attention Deficit Disorder with Hyperactivity, Blood Pressure, Child, Dose-Response Relationship, Drug, Fatigue, Female, Headache, Humans, Disorders of Excessive Somnolence, Male, Time Factors, Guanfacine, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD. https://app.cochat.ai/papers/10.1017/s1092852900017107
- The paper
- Biederman, J., Melmed, R. D., Patel, A., McBurnett, K., Donahue, J., & Lyne, A. (2008). Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents with ADHD. CNS Spectrums. https://doi.org/10.1017/s1092852900017107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.